


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound according to the general Formula (I)




the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the *N*-oxide form thereof, wherein:


X is CH₂, N-R⁷, S or O ;

R⁷ is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, alkylcarbonyl, alkyloxycarbonyl and mono- and dialkylaminocarbonyl;

B is a radical, optionally substituted with *r* radicals R¹, according to anyone of Formula (B-a) or (B-b) and fused to the isoxazolinyl moiety by either of the bond pairs (c,d), (d,e) or (e,f)



(B-a)



(B-b)

wherein

Het is an optionally substituted 5- or 6-membered heterocyclic ring, selected from

the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, oxadiazolyl and triazolyl ;


each R^1 is, independently from each other, selected from the group consisting of hydrogen, hydroxy, amino, nitro, cyano, halo and alkyl and, only when R^1 is attached to a *N*-atom, is further selected from the group of alkyloxyalkyl, alkyloxyalkyloxyalkyl, alkyloxycarbonylalkyl, formyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl and mono- and dialkylamino-carbonyl ;

r is an integer ranging from 0 to 6 ;

a and b are asymmetric centers ;

$(CH_2)_m$ is a straight hydrocarbon chain of m carbon atoms, m being an integer ranging from 1 to 4 ;

Pir is a radical according to any one of Formula (IIa), (IIb) or (IIc)



optionally substituted with n radicals R^8 , wherein :

each R^8 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo and alkyl ;

n is an integer ranging from 0 to 5 ;

R^9 is selected from the group consisting of hydrogen, alkyl and formyl ;


R^3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system together with an optionally substituted and partially or completely hydrogenated hydrocarbon chain of 1 to 6 atoms long with which said ring system is attached to the Pir radical and of which may contain one or more

heteroatoms selected from the group of O, N and S;

Ar is phenyl or naphthyl, optionally substituted with one or more halo, cyano, oxo, hydroxy, alkyl, formyl, alkyloxy or amino radicals ; and

alkyl represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals.

2. (Currently Amended) A compound according to claim 1, characterized in that R^3 is a radical according to any one of Formula (IIIa), (IIIb) or (IIIc)



wherein :

d is a single bond while Z is a bivalent radical selected from the group consisting of $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{CH}(\text{OH})-$, $-\text{C}(=\text{N}-\text{OH})-$, $-\text{CH}(\text{alkyl})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{NH}-$ and $-\text{SH}-$; or d is a double bond while Z is a trivalent radical of formula $=\text{CH}-$ or $=\text{C}(\text{alkyl})-$;

A is a 5- or 6-membered aromatic homocyclic or heterocyclic ring, selected from the group consisting of phenyl, pyranyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, oxadiazolyl and isoxazolyl ;

p is an integer ranging from 0 to 6 ;

R^4 and R^5 are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, biphenyl, halo and cyano ; or

R^4 and R^5 may be taken together to form a bivalent radical $-R^4-R^5-$ selected from the group consisting of $-CH_2-$, $=CH-$, $-CH_2-CH_2-$, $-CH=CH-$, $-O-$, $-NH-$, $=N-$, $-S-$, $-CH_2N(-alkyl)-$, $-N(-alkyl)CH_2-$, $-CH_2NH-$, $-NHCH_2-$, $-CH=N-$, $-N=CH-$, $-CH_2O-$ and $-OCH_2-$;

each R^6 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo, carboxyl, alkyl, Ar, alkyloxy, Ar-oxy, alkylcarbonyloxy, alkyloxycarbonyl, alkylthio, mono- and di(alkyl)amino, alkylcarbonylamino, mono- and di(alkyl)aminocarbonyl, mono- and di(alkyl)aminocarbonyloxy, mono- and di(alkyl)aminoalkyloxy ; or

two vicinal radicals R^6 may be taken together to form a bivalent radical $-R^6-R^6-$ selected from the group consisting of $-CH_2-CH_2-O-$, $-O-CH_2-CH_2-$, $-O-CH_2-C(=O)-$, $-C(=O)-CH_2-O-$, $-O-CH_2-O-$, $-CH_2-O-CH_2-$, $-O-CH_2-CH_2-O-$, $-CH=CH-CH=CH-$, $-CH=CH-CH=N-$, $-CH=CH-N=CH-$, $-CH=N-CH=CH-$, $-N=CH-CH=CH-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-C(=O)-$, $-C(=O)-CH_2-CH_2-$, $-CH_2-C(=O)-CH_2-$ and $-CH_2-CH_2-CH_2-CH_2-$ and

R^{16} is selected from the group consisting of hydrogen, alkyl, Ar and Ar-alkyl.

3. (Currently Amended) A compound according to claim 2, wherein characterized in ~~that~~ $X = O$; $m = 1$; B is a radical according to Formula (B-a) or (B-b), Pir is a radical according to Formula (IIa) wherein $n = 0$; R^3 is a radical according to according to any one of Formula (IIIa), (IIIb) or (IIIc) wherein d is a double bond while Z is a trivalent radical of formula $=CH-$ or $=C(alkyl)-$; A is a phenyl ring; R^4 is hydrogen or alkyl ; R^5 and R^{16} are each hydrogen ; R^6 is hydrogen or halo and $p = 1$.

4. (Currently Amended) A compound according to claim 1, ~~any one of claims 1 to 3~~, wherein ~~characterized in that~~ Het is selected from the group consisting of pyridinyl, thienyl and pyrrolyl, each radical optionally substituted on a N atom with a radical selected from the group

consisting of hydrogen, alkyl, hydroxyalkyl, alkyloxyalkyloxyalkyl, alkyloxycarbonylalkyl, alkylcarbonyl, alkyloxycarbonyl and alkyloxyalkylcarbonyl.

5. (Currently Amended) A compound which is degraded *in vivo* to yield a compound according to claim 1, ~~any one of claims 1 to 4~~.

6. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 5~~ for use as a medicine.

7. (Currently Amended) The use of a compound according to claim 1 ~~any one of claims 1 to 5~~ for the manufacture of a medicament for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders.

8. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 5~~.

9. (Currently Amended) A process for making a pharmaceutical composition ~~according to claim 8~~, comprising mixing a compound according to claim 1 ~~any one of claims 1 to 5~~ and a pharmaceutically acceptable carrier.

10. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 5~~ and one or more other compounds selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs.

11. (Canceled)

12. (Currently Amended) A method for ~~The use of a compound according to any one of claims 1 to 5~~ for the manufacture of a medicament for the treatment and/or prophylaxis of

depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders, said treatment comprising the simultaneous or sequential administration of a therapeutic amount of a compound according to claim 1 ~~any one of claims 1 to 5~~ and a therapeutic amount of one or more other compounds selected from the group of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's drugs.

13. (Currently Amended) A process for making a pharmaceutical composition ~~according to claim 10~~, comprising mixing a compound according to claim 1 ~~any one of claims 1 to 5~~ and a compound selected from the group of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's disease drugs and a pharmaceutically acceptable carrier.